Cardiovascular disease. Part 3: Dyslipidaemia and atherosclerosis (AJP Nov 2019)

Accredited CPD
Group 2

Provider: Australian Journal of Pharmacy
Author: Louis Roller and Jenny Gowan

CPD Credits: 4

Overview 

This is the third article of the cardiovascular disease series, which focuses on dyslipidaemia and atherosclerosis

Learning Objectives

After completing this activity, pharmacists should be able to:

  1. discuss the current goals for lipid lowering therapy in Australia;
  2. interpret the significance of total cholesterol, triglycerides, high density lipoprotein-cholesterol and atherogenic risk factors of low-density lipoprotein-cholesterol;
  3. summarise available lipid-lowering treatments;
  4. list possible side effects and drug interactions of the key lipid modifying drugs and how to manage these in practice;
  5. discuss the importance of the new PKSKG9 inhibitors;
  6. identify barriers to adherence;
  7. differentiate between the various type of muscle problems associated with statins;
  8. provide advice on dietary measures and supplements used in conjunction with lipid lowering medications

The 2016 Competency Standards addressed by this activity include: 1.4, 1.5, 2.1, 2.2, 2.3, 2.4, 3.1, 3.2, 3.3, 3.5, 3.6, 5.3

Accreditation number: CX19058    Accreditation expires: 1/11/2021
This activity has been accredited for 2.0 hours of Group One CPD (or 2.0 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan, which may be converted to 2.0 hours of Group Two CPD (or 4.0 CPD credits) upon successful completion of the associated assessment activity.